Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
Preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing antibodies target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with HAd5 expressing the nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and k18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral antigens, even if they are not a target of neutralizing antibodies, to broaden epitope coverage and immune effector mechanisms.Keywords
All Related Versions
- Published version: The Journal of Immunology, 207 (2), 376.
This publication has 8 references indexed in Scilit:
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunityCell, 2021
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunitymedRxiv, 2021
- Cutting Edge: Mouse SARS-CoV-2 Epitope Reveals Infection and Vaccine-Elicited CD8 T Cell ResponsesThe Journal of Immunology, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired functionNature Immunology, 2020
- Retrograde migration supplies resident memory T cells to lung-draining LN after influenza infectionJournal of Experimental Medicine, 2020
- Virus-specific T cells as correlate of (cross-)protective immunity against influenzaVaccine, 2015
- Intravascular staining for discrimination of vascular and tissue leukocytesNature Protocols, 2014